These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 8492409)

  • 1. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
    Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
    Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
    Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
    Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T
    Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
    Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
    Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.
    Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G
    Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
    Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
    Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)].
    Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K
    Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
    Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
    Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
    Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment for a high-risk group for childhood acute lymphoblastic leukemia].
    Koizumi S
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1042-9. PubMed ID: 10431575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
    J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)].
    Mimaya J; Horikoshi Y; Shimizu H; Maeda H; Koizumi S; Kawakami K; Watanabe A; Utsumi J; Kikuta A; Oka T; Mugishima H; Kawamura N; Gushiken T; Ohta S; Yamamura Y; Ishida Y; Sekine I; Okada N; Fujimoto T
    Rinsho Ketsueki; 1997 Feb; 38(2):100-7. PubMed ID: 9059063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
    de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
    Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
    Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
    Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The Munich study on the treatment of acute lymphoblastic leukemia in childhood (ALL 77-02)].
    Graubner UB; Haas RJ; Janka G; Gaedicke G; Kohne E; Rieber EP
    Klin Padiatr; 1985; 197(3):207-14. PubMed ID: 3892149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.
    Cortes J; Fayad L; O'Brien S; Keating M; Kantarjian H
    Clin Cancer Res; 1999 Sep; 5(9):2491-7. PubMed ID: 10499624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.